Infliximab treatment also prevented changes in membrane expression of GluA1 and GluA2 subunits of AMPA receptors and NR2A and NR2B subunits of NMDA receptors and normalized cognitive deficits. This evidence concerns the gene GRIA1 and Cognitive impairment.